Covidien Receives FDA Approval for Nellcor

The U.S. Food and Drug Administration has granted Covidien 510(k) clearance to market the company’s Nellcor Bedside SpO2 Patient Monitoring System.

Advertisement

The Nellcor Bedside SpO2 system with OxiMax technology continuously monitors SpO2 and pulse rate for adult, pediatric and neonatal patients, giving clinicians instant access to comprehensive trending respiratory information. The system also includes technology to help differentiate between serious and minor events and reduce clinically insignificant oxygen desaturation alarms.

Learn more about Covidien.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.